RESUMO
BACKGROUND: Only clinically validated HPV assays can be accepted in cervical cancer screening. OBJECTIVES: To update the list of high-risk HPV assays that fulfil the 2009 international validation criteria (Meijer-2009). DATA SOURCES: PubMed/Medline, Embase, Scopus, references from selected studies; published in January 2014 to August 2020. STUDY ELIGIBILITY CRITERIA: HPV test validation studies and primary screening studies, involving testing with an index HPV test and a comparator HPV test with reporting of disease outcome (occurrence of histologically confirmed cervical precancer; CIN2+). PARTICIPANTS: Women participating in cervical cancer screening. INTERVENTIONS: Testing with an index and a comparator HPV test of clinician-collected cervical specimens and assessment of disease outcome (Assuntos
Alphapapillomavirus
, Detecção Precoce de Câncer
, Papillomaviridae/isolamento & purificação
, Infecções por Papillomavirus
, Neoplasias do Colo do Útero
, Feminino
, Técnicas de Genotipagem
, Humanos
, Infecções por Papillomavirus/diagnóstico
, Reprodutibilidade dos Testes
, Sensibilidade e Especificidade
, Neoplasias do Colo do Útero/diagnóstico
, Neoplasias do Colo do Útero/virologia
